Condition: Bipolar I Disorder · Sponsor: LB Pharmaceuticals Inc.
Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.
This description comes directly from the study's public registry record.
George Nomikos · (212) 605-0300 · clinicaltrials@lbpharma.us
Always discuss trial participation with your own doctor first.
| Pillar Clinical Research | Bentonville, Arkansas, United States | Recruiting |
| Pillar Clinical Research | Little Rock, Arkansas, United States | Recruiting |
| CenExel | Bellflower, California, United States | Recruiting |
| ProScience Research Group | Culver City, California, United States | Recruiting |
| CenExel | Garden Grove, California, United States | Recruiting |
| Synergy San Diego | Lemon Grove, California, United States | Recruiting |
| NRC Research Institute | Los Angeles, California, United States | Recruiting |
| NRC Research Institute | Orange, California, United States | Recruiting |
| CenExel | Riverside, California, United States | Recruiting |
| CenExel | Torrance, California, United States | Recruiting |
| St. Jude Clinical Research | Doral, Florida, United States | Recruiting |
| Cenexel Hollywood Florida | Hollywood, Florida, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07494305